首页 | 本学科首页   官方微博 | 高级检索  
     

聚乙二醇干扰素α-2a联合短程拉米夫定治疗HBeAg阳性慢性乙型肝炎的疗效
引用本文:黄湛镰,赵志新,邓洪,张宇锋,卢翠容,高志良. 聚乙二醇干扰素α-2a联合短程拉米夫定治疗HBeAg阳性慢性乙型肝炎的疗效[J]. 中华肝脏病杂志, 2010, 18(6). DOI: 10.3760/j.issn.1007-3418.2010.06.006
作者姓名:黄湛镰  赵志新  邓洪  张宇锋  卢翠容  高志良
作者单位:中山大学附属第三医院感染科,广州,510630
基金项目:中山大学5010计划 
摘    要:
目的 探讨通过短程联合拉米夫定以提高聚乙二醇干扰素α-2a 疗效的新治疗方法.方法 所有患者以聚乙二醇干扰素α-2a 135μg开始治疗,在治疗12周时,若HBV DNA或HBeAg转阴,继续单独使用干扰素治疗至52周(A组),未达到上述条件者(B组)分为B1组及B2组,B1组短程联合拉米夫定治疗12周后继续干扰素治疗并完成52周疗程,B2组继续单独用干扰素治疗并完成52周疗程.符合正态分布的计量资料采用t检验;符合偏态分布的计量资料用中位数(全距)表示,采用秩和检验.结果共有58例患者入组,8例患者在治疗12周时出现HBV DNA或HBeAg转阴,单用干扰素完成52周疗程,治疗结束时HBV DNA转阴率、HBeAg血清学转换率,HBsAg转阴率及ALT复常率分别为8/8、6/8、0/8及8/8.B1组患者24例,治疗52周时HBV DNA转阴率、HBeAg血清学转换率,HBsAg转阴率及ALT复常率分别为50%(12/24)、38%(9/24)、4%(1/24)及63%(15/24);B2组患者26例,治疗52周时HBV DNA转阴率、HBeAg血清学转换率,HBsAg转阴率及ALT复常率分别为31%(8/26)、27%(7/26)、O(0/26)及35%(9/26).结论 聚乙二醇干扰素α-2a治疗取得早期应答的患者治疗52周的应答率高;通过对早期疗效不佳的患者短程联合拉米夫定治疗,可提高干扰素的疗效,但有待更大样本量的随机临床试验证实.

关 键 词:肝炎,乙型,慢性  治疗  干扰素  拉米夫定  联合疗法

A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients
HUANG Zhan-lian,ZHAO Zhi-xin,DENG Hong,ZHANG Yu-feng,LU Cui-rong,GAO Zhi-liang. A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients[J]. Chinese journal of hepatology, 2010, 18(6). DOI: 10.3760/j.issn.1007-3418.2010.06.006
Authors:HUANG Zhan-lian  ZHAO Zhi-xin  DENG Hong  ZHANG Yu-feng  LU Cui-rong  GAO Zhi-liang
Abstract:
Objective To investigate the efficacy of by combining a 12-week course of lamivudine in those HBeAg-positive hepatitis B patients receiving peginterferon alfa-2a (peg-IFN α-2a) therapy. Methods A total of 58 patients initiated a 52-week course of peginterferon alfa-2a were enrolled and divided into 3 groups. The patients with HBV DNA undetectable or HBeAg negative at week 12 were divided into group A, in this group treatment continued to week 52 with peg-IFN α -2a alone; The rest paitents were divided into group Bl and B2, in group Bl, lamivudine was combined at a course of 12 weeks, while in group B2 treatment continued to week 52 with peg-IFN α -2a alone. Clinical responses were assessed at week 52. Results 8 out of 58 patients achieved undetectable HBV DNA or HBeAg loss at week 12 and divide into group A. In this group the HBV DNA loss rate, HBeAg seroconversion rate, HBsAg loss rate and ALT normalization rate were 100% (8/8), 75% (6/8), 0% (0/8) and 100% (8/8) respectively at the end of treatment. In this group the HBV DNA loss rate, HBeAg seroconversion rate, HBsAg loss rate and ALT normalization rate were 100% (8/8), 75% (6/8), 0% (0/8) and 100%(8/8) respectively at the end of treatment. The rest 50 patients without early response to peg-IFN α -2a at week 12 were divided into group Bl (24 patients enrolled) and B2 (26 patients). At the end of treatment, the HBV DNA loss rate, HBeAg seroconversion rate, HBsAg loss rate and ALT normalization rate in Group B1 were 50% (12/24), 38% (9/24), 4% (1/24) and 63% (15/24) respectively, and 31% (8/26), 27% (7/26), 0% (0/26) and 35% (9/26) respectively in group B2. Conclusions Those patients with early responses to peg-IFN α -2a therapy can achieve high clinical responses at the end of 52-week treatment. The combining therpay of lamivudine for a course of 12-weeks can improve the clinical responses for the patients without early responses to peg-IFN α-2a.
Keywords:Hepatitis B,chronic  Treatment  Interferon  Lamivudine  Combination therapy
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号